A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

FRANKFURT: European shares extended gains on Monday, with most sub-indexes rising, as investors remained optimistic about ...

Novo Nordisk (NVO) closed the latest trading day at $62.62, indicating a +0.87% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.06%. At the same time, the Dow ...

Welltower forecast annual funds from operations (FFO) above estimates on Monday, betting on strong demand for the healthcare real estate investment trust's assisted living and senior housing ...

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Novo Nordisk (NVO) has launched its weight-loss drug Wegovy in Thailand, Reuters reported on Monday, citing an executive of ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...